AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions
- Details
- Category: AstraZeneca
AstraZeneca today announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.
Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant's RVT-3101, a novel TL1A directed antibody.
AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
- Details
- Category: Bayer
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023.
FDA approves PENBRAYA™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
CPHI Annual Survey: global pharma resilient with India the chief beneficiary of macro changes
- Details
- Category: Business
Ahead of this month's CPHI Barcelona - the world's largest pharma event, held at Fira Barcelona (October 24-26th, 2023) - and CPHI & PMEC India to be held at India Expo Centre, Greater Noida, Delhi NCR (November 28-30) key highlights from the CPHI pharma survey are announced. The full findings will be published at CPHI Barcelona as part of the CPHI Annual Report.
U.S. FDA approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
More Pharma News ...
- Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
- Pfizer presents new data at IDWeek 2023 highlighting advances in prevention and treatment of certain respiratory illnesses and other infectious diseases
- Bayer to partner with Twist Bioscience to accelerate drug discovery
- Novartis shareholders approve the proposed 100% Spin-off of Sandoz
- Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
- GSK and Save the Children renew award-winning partnership, with focus on 'zero dose' children who have never received a vaccine
- Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer